What is BPC-157?
BPC-157 free base is a 15-amino-acid fragment of BPC, as described in FDA's July 2026 briefing. BPC-157 10MG is the catalogue's vial presentation. A shorter BPC-157 product name does not independently establish the vial's salt form or contents. FDA BPC-157 assessment.
The briefing can explain what BPC-157 free base means without demonstrating that a named vial, tablet, capsule or pen matches the material it reviewed. The listed 10MG is an amount attached to this presentation, not evidence of a therapeutic result. FDA BPC-157 assessment.
BPC-157 human-study evidence
In its July 2026 review, FDA found the reported ulcerative-colitis enema-study data inadequate to support BPC-157 efficacy and safety for that use. That assessment concerns the reported enema formulation for ulcerative colitis. FDA BPC-157 assessment.
FDA also distinguished the studied enema from the rectal suppository proposed in the nomination. Even within the same disease area, the two formulations were not treated as interchangeable evidence. Neither is the catalogue's 10MG vial. FDA BPC-157 assessment.
BPC-157 safety concerns
FDA's compounding safety communication identifies potential immune-response risks, peptide-related impurities and difficulties characterizing the active ingredient in compounded BPC-157. These concerns address the compounded substance and proposed routes. They are not a finding that this supplier vial is contaminated, nor evidence that the vial produces a clinical benefit. FDA compounding safety communication.
For the broader substance context, see the BPC-157 guide. The BPC-157 10mg Pen is separately documented; its name does not establish equivalence to the vial.
